NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
387 trialsNCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT07459998 2026-03-10
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07460375 2026-03-10
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT05951608 2026-03-05
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT06596473 2026-03-05
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07387068 2026-03-04
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT05109975 2026-02-27
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT07438093 2026-02-27
Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
The First Affiliated Hospital of Xiamen University
Phase NA Not yet recruiting
NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT07412665 2026-02-17
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
NCT06779851 2026-02-13
SUMMIT-1
Bright Peak Therapeutics Inc
Phase 1 Active not recruiting
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07328217 2026-02-11
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT06480552 2026-02-05
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT07359066 2026-02-05
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT06697197 2026-02-03
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07266428 2026-02-03
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
NCT04626635 2026-02-02
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07380386 2026-02-02
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07377591 2026-01-30
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT07042100 2026-01-22
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT07093970 2026-01-22
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT05868915 2026-01-21
HV-101 for Patients With Advanced Solid Tumors
Hervor Therapeutics
Phase 1 Terminated
NCT06770569 2026-01-21
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Recruiting
NCT07356453 2026-01-21
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
Phase 1 Recruiting
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT06927570 2026-01-16
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07186452 2026-01-16
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT07349160 2026-01-16
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1 Recruiting
NCT07253116 2026-01-14
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2 Recruiting
NCT06741644 2026-01-09
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06990464 2026-01-08
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT07131202 2026-01-08
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2 Recruiting
NCT07327294 2026-01-08
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Evopoint Biosciences Inc.
Phase 1/2 Not yet recruiting
NCT05774873 2026-01-06
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT07252414 2026-01-05
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05277168 2026-01-02
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT06384352 2026-01-02
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting